登录注册

IL-21 and CXCR6+ CD8+ T cells drive checkpoint inhibitor-associated thyroid autoimmunity

Science Translational Medicine

Immune checkpoint inhibitors can cause endocrine autoimmune side effects. IL-21, a soluble molecule involved in activating the immune system, is a potential therapeutic target to help reduce endocrine autoimmune side effects caused by checkpoint inhibitor cancer therapy. A specific group of CD8+ immune cells with strong killing activity, called CXCR6+ IFN-g+ cytotoxic CD8+ T cells, play a central role in this autoimmune attack, controlled by IL-21. Blocking IL-21 prevented thyroid autoimmunity.

Related products

Catalog No.	Product Name	Description	Target
HV658016	Anti-Human IL-21 Reference Antibody (Avizakimab	Research Grade Avizakimab (HV658016) is a humanized monoclonal antibody detecting IL-21 in ELISA, Bioactivity: FACS, Functional assay, Research in vivo. Suitable for Human. Highlights ●Multi-Application — Validated across multiple applications.	IL-21, Interleukin-21, IL21, Za11

7X24小时产品咨询热线：027--87433958(9:00-18:00)，或扫描下方产品专员二维码或在线留言
武汉东湖新技术开发区神墩四路666号研发楼B区3层东

24小时产品查询
扫一扫关注我们
专属渠道经理

鄂ICP备2023002448号-2

重组蛋白

抗体

试剂盒

实验相关试剂

IL-21 and CXCR6+ CD8+ T cells drive checkpoint inhibitor-associated thyroid autoimmunity